NO995419L - Intravaginale anordninger for legemiddelavlevering for administrering av testosteron og testosteron-forløpere - Google Patents

Intravaginale anordninger for legemiddelavlevering for administrering av testosteron og testosteron-forløpere

Info

Publication number
NO995419L
NO995419L NO995419A NO995419A NO995419L NO 995419 L NO995419 L NO 995419L NO 995419 A NO995419 A NO 995419A NO 995419 A NO995419 A NO 995419A NO 995419 L NO995419 L NO 995419L
Authority
NO
Norway
Prior art keywords
testosterone
administration
drug delivery
delivery devices
precursors
Prior art date
Application number
NO995419A
Other languages
English (en)
Norwegian (no)
Other versions
NO995419D0 (no
Inventor
Clare Passmore
Claire Gilligan
Original Assignee
Galen Chemicals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galen Chemicals Ltd filed Critical Galen Chemicals Ltd
Publication of NO995419D0 publication Critical patent/NO995419D0/no
Publication of NO995419L publication Critical patent/NO995419L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO995419A 1997-05-07 1999-11-05 Intravaginale anordninger for legemiddelavlevering for administrering av testosteron og testosteron-forløpere NO995419L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE970333 1997-05-07
PCT/IE1998/000033 WO1998050016A2 (en) 1997-05-07 1998-05-07 Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors

Publications (2)

Publication Number Publication Date
NO995419D0 NO995419D0 (no) 1999-11-05
NO995419L true NO995419L (no) 2000-01-07

Family

ID=11041465

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995419A NO995419L (no) 1997-05-07 1999-11-05 Intravaginale anordninger for legemiddelavlevering for administrering av testosteron og testosteron-forløpere

Country Status (15)

Country Link
US (1) US6416780B1 (ja)
EP (1) EP0981327B1 (ja)
JP (1) JP2001524124A (ja)
CN (1) CN1184957C (ja)
AT (1) ATE227120T1 (ja)
AU (1) AU741482B2 (ja)
CA (1) CA2288046C (ja)
DE (1) DE69809222T2 (ja)
DK (1) DK0981327T3 (ja)
ES (1) ES2187024T3 (ja)
IL (1) IL132702A0 (ja)
NO (1) NO995419L (ja)
NZ (1) NZ501236A (ja)
PT (1) PT981327E (ja)
WO (1) WO1998050016A2 (ja)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
ES2388731T5 (es) * 2002-03-27 2018-01-19 Warner Chilcott (Ireland) Limited Dispositivos de administración de fármacos mediante una matriz intravaginal
US8404272B2 (en) 2003-06-26 2013-03-26 Poly-Med, Inc. Fiber-reinforced composite rings for intravaginal controlled drug delivery
US8399013B2 (en) * 2003-06-26 2013-03-19 Poly-Med, Inc. Partially absorbable fiber-reinforced composites for controlled drug delivery
US7922702B2 (en) 2004-07-02 2011-04-12 Qlt Inc. Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device
MY144968A (en) 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
MY145694A (en) 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
JP5265359B2 (ja) 2005-08-11 2013-08-14 マサチューセッツ インスティテュート オブ テクノロジー 膀胱内薬物送達デバイスおよび方法
US8795711B2 (en) 2006-03-31 2014-08-05 Mati Therapeutics Inc. Drug delivery methods, structures, and compositions for nasolacrimal system
US8466188B2 (en) 2006-10-12 2013-06-18 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
EP2231254B9 (en) * 2007-12-11 2015-04-08 Massachusetts Institute of Technology Implantable drug delivery device
DK2359807T3 (en) 2008-02-04 2017-10-16 Ferring Bv Monolithic vaginal rings comprising progesterone and methods of preparation and use thereof
US9034365B2 (en) 2008-05-20 2015-05-19 Poly-Med, Inc. Biostable, multipurpose, microbicidal intravaginal devices
KR101794899B1 (ko) * 2008-08-09 2017-11-07 메사츄세츠 인스티튜트 어브 테크놀로지 남성 비뇨생식기 및 주위 조직을 치료하는 방법 및 체내이식형 약물 전달 장치
US8101647B2 (en) 2008-10-17 2012-01-24 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
EP2942350A1 (en) 2008-10-17 2015-11-11 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
US20110269788A1 (en) 2008-12-29 2011-11-03 Xenon Pharmaceuticals Inc. Spiro-oxindole-derivatives as sodium channel blockers
CN102470237A (zh) 2009-06-26 2012-05-23 塔里斯生物医药公司 用于可植入药物递送装置的固体药物片剂
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
US9017312B2 (en) 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
RU2015103694A (ru) 2009-10-14 2015-06-27 Ксенон Фармасьютикалз Инк. Способы синтеза спиро-оксиндольных соединений
PE20121699A1 (es) 2010-02-26 2012-12-22 Xenon Pharmaceuticals Inc Composiciones farmaceuticas del compuesto espiro-oxindol para administracion topica
SG191893A1 (en) 2011-01-10 2013-08-30 Taris Biomedical Inc Lidocaine regimen for the use of sustained treatment of bladder pain and irritative voiding
ES2637388T3 (es) 2011-02-04 2017-10-13 Taris Biomedical, Inc. Dispositivo implantable para la liberación controlada de un fármaco de baja solubilidad
US9974685B2 (en) 2011-08-29 2018-05-22 Mati Therapeutics Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
CN103889401B (zh) 2011-08-29 2017-10-13 Qlt公司 持续释放递送活性剂以治疗青光眼和高眼压
BR112014010271A2 (pt) 2011-10-31 2017-04-18 Xenon Pharmaceuticals Inc compostos de benzenossulfonamida e seu uso como agentes terapêuticos
AU2014228858A1 (en) 2013-03-15 2015-09-10 The Regents Of The University Of California Dual reactivity potent Kunitz inhibitor of fibrinolysis
SG10201708522SA (en) 2013-03-15 2017-12-28 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
CA2919215C (en) 2013-08-19 2022-11-29 Taris Biomedical Llc Multi-unit drug delivery devices and methods
CN104546668B (zh) * 2013-10-23 2019-03-05 国家卫生计生委科学技术研究所 液体硅橡胶为载体的药物缓控释系统的制备及应用
ES2699003T3 (es) * 2014-06-28 2019-02-06 Laboratorios Andromaco S A Pesario de cerclaje que contiene progesterona de liberación prolongada, sostenida y continua, usado para la prevención de partos prematuros
AR103636A1 (es) 2015-02-05 2017-05-24 Teva Pharmaceuticals Int Gmbh Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
JP7425534B2 (ja) 2015-04-23 2024-01-31 タリス バイオメディカル エルエルシー 薬物透過性構成要素を有する薬物送達デバイス及び方法
CA3014395A1 (en) 2016-02-19 2017-08-24 Phoenix Molecular Designs Carboxamide derivatives useful as rsk inhibitors
CN109526219B (zh) 2016-05-20 2021-03-12 泽农医药公司 苯磺酰胺及其作为治疗剂的用途
BR112019011121A2 (pt) 2016-12-09 2019-10-01 Xenon Pharmaceuticals Inc compostos de benzenossulfonamida e seu uso como agentes terapêuticos
CN112262142B (zh) 2018-06-13 2023-11-14 泽农医药公司 苯磺酰胺化合物及其作为治疗剂的用途
PE20211065A1 (es) 2018-07-27 2021-06-09 Xenon Pharmaceuticals Inc Metodo para tratar la epilepsia
US10752623B2 (en) 2018-08-31 2020-08-25 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors
CR20210099A (es) 2018-08-31 2021-06-24 Xenon Pharmaceuticals Inc Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapèuticos
US11813354B1 (en) 2019-01-11 2023-11-14 Shear Kershman Laboratories, Inc Trans-mucosal delivery system for testosterone
WO2020165646A1 (en) 2019-02-11 2020-08-20 Phoenix Molecular Designs Crystalline forms of an rsk inhibitor
AU2022349462A1 (en) 2021-09-24 2024-04-11 Xenon Pharmaceuticals Inc. Pyridine derivatives and their use as sodium channel activators
WO2023049369A2 (en) 2021-09-24 2023-03-30 Xenon Pharmaceuticals Inc. Pyridinyl derivatives as sodium channel activators
KR20240070604A (ko) 2021-09-24 2024-05-21 제논 파마슈티칼스 인크. 소듐 채널 활성화제로서 피리디닐아세트아미드 유도체
WO2023239729A1 (en) 2022-06-08 2023-12-14 Xenon Pharmaceuticals Inc. Pyridinamine derivatives and their use as potassium channel modulators

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3920805A (en) * 1971-12-09 1975-11-18 Upjohn Co Pharmaceutical devices and method
GB2079158B (en) * 1980-06-09 1985-01-09 Ahi Operations Ltd Intra-vaginal devices
US5340585A (en) * 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
IL116433A (en) * 1994-12-19 2002-02-10 Galen Chemicals Ltd INTRAVAGINAL DRUG DELIVERY DEVICES FOR THE ADMINISTRATION OF 17β-OESTRADIOL PRECURSORS

Also Published As

Publication number Publication date
ATE227120T1 (de) 2002-11-15
ES2187024T3 (es) 2003-05-16
CN1184957C (zh) 2005-01-19
US6416780B1 (en) 2002-07-09
AU7446998A (en) 1998-11-27
DK0981327T3 (da) 2003-03-10
WO1998050016A2 (en) 1998-11-12
JP2001524124A (ja) 2001-11-27
CA2288046A1 (en) 1998-11-12
CA2288046C (en) 2006-10-03
DE69809222D1 (de) 2002-12-12
AU741482B2 (en) 2001-11-29
DE69809222T2 (de) 2003-08-14
NZ501236A (en) 2002-02-01
CN1255056A (zh) 2000-05-31
EP0981327B1 (en) 2002-11-06
NO995419D0 (no) 1999-11-05
EP0981327A2 (en) 2000-03-01
PT981327E (pt) 2003-02-28
IL132702A0 (en) 2001-03-19
WO1998050016A3 (en) 1999-02-04

Similar Documents

Publication Publication Date Title
NO995419D0 (no) Intravaginale anordninger for legemiddelavlevering for administrering av testosteron og testosteron-forlöpere
AU1227899A (en) Osmotic medicament releasing system
GB2341550A (en) Gastroretentive controlled release microspheres for improved drug delivery
WO2003077972A3 (en) Implantable drug delivery system
WO2003028660A3 (en) Drug delivery devices and methods
ES2192226T3 (es) Composicion farmaceutica oral que contiene agentes activos antimicrobianos y pantoprazol de liberacion prolongada.
GB2338414A (en) Intravesical drug delivery system
ID21259A (id) Sistim penyaluran obat untuk dua atau lebih bahan-bahan aktif
EP1504758A3 (en) Controlled-release formulations coated with aqueous dispersions of ethylcellulose
AU4399196A (en) Intravaginal drug delivery devices for the administration of 17beta -oestradiol precursors
AR036972A1 (es) Tableta bioadhesiva de hidratacion progresiva y liberacion sostenida y su uso en la fabricacion de un agente farmaceutico
AU4121297A (en) Galenic form with extended release of milnacipran
EP1499300A4 (en) PHARMACEUTICAL FORMULATIONS WITH IMPROVED BIOAVAILABILITY
ATE391495T1 (de) Matrixsystem mit verzögerter freisetzung für hochlösliche wirkstoffe
HK1032010A1 (en) Medicament formulation with a controlled release of an active agent.
MY130332A (en) Pharmaceutical formulation comprising iota-carrageenan and at least one neutral gelling polymer
AU1495595A (en) Sustained-release dosage forms of alfuzosin hydrochloride
HRP20010684B1 (en) Directly compressible matrix for controlled release of single daily doses of clarithromycin
EP1106609A3 (en) Aminoalcohol derivative and medicament comprising the same
WO2002053149A3 (de) Arzneimittel enthaltend ein polyamin als wirksubstanz
BG106342A (en) Low-dose tablets and preparation method
WO1998038985A3 (en) Use of carvedilol for the manufacture of a medicament for preventive and therapeutic treatment of inflammatory diseases
PT8662T (pt) Doseador para distribuir um medicamento inoforo aplicado em especial para tratamento de animais
MX9606041A (es) Forma de dosificacion de rapida disolucion.
MX9605633A (es) Composicion farmaceutica, metodo y dispositivo para prevenir o tratar resequedad de los ojos o enfermedad ocasionada por la misma.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application